[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123). 1st communication. Efficacy activity spectrum--resistance in therapy (author's transl)].
The clinical trial of the combination N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) showed that, when given in the ratio of 5:1 and in a suitable dosage computed from pharmacokinetic information, it exhibited antibacterial activity and had a therapeutic effect in about 90% of the patients. In view of the numerous types of pathogen identified in the clinical trial, CN 3123 can be described as a broad-spectrum chemotherapeutic agent. CN 3123 was also effective against infections caused by sulfonamide-resistant or antibiotic-resistant pathogens.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D013423:Sulfamoxole / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology; D014295:Trimethoprim / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D013449:Sulfonamides; D014295:Trimethoprim; D013423:Sulfamoxole
Klinische Prüfung der antibakteriellen Kombination Sulfamoxol/Trimethoprim (CN 3123). 1. Mitteilung: Wirksamkeit--Wirkungsspektrum--Resistenz bei therapeutischer Anwendung